Nemes Rush Group
CRL icon

Nemes Rush Group’s Charles River Laboratories CRL Stock Holding History

Nemes Rush Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-5
Closed -$1.13K – 944
2026
Q2 		$1.13K Hold
5
– – ﹤0.01% 852
2026
Q1 		$863 Buy
+5
New +$927 ﹤0.01% 842
2025
Q4 		– Sell
-2
Closed -$313 – 994
2025
Q3 		$313 Hold
2
– – ﹤0.01% 665
2025
Q2 		$303 Hold
2
– – ﹤0.01% 701
2025
Q1 		$301 Hold
2
– – ﹤0.01% 689
2024
Q4 		$369 Buy
+2
New +$385 ﹤0.01% 707

Other funds holding CRL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Cooke & Bieler
Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Van Berkom & Associates
Van Berkom & Associates Montreal, Quebec, Canada $2.81B AUM 6.02% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Nemes Rush Group's CRL Position: Q3 2026 in Review

Nemes Rush Group sold out of Charles River Laboratories (CRL) in Q3 2026, closing a stake of 5 shares — an estimated $1.13K sold.

Nemes Rush Group first reported a position in CRL in Q4 2024 and held it in 6 quarters. The position peaked at $1.13K in Q2 2026. 285 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Nemes Rush Group reported no remaining Charles River Laboratories position as of Q3 2026 after selling out during the quarter.
  • Nemes Rush Group sold 5 Charles River Laboratories shares in Q3 2026, an estimated $1.13K.
  • Nemes Rush Group first reported a position in Charles River Laboratories in Q4 2024 and held it in 6 quarters.
  • Nemes Rush Group's Charles River Laboratories position peaked at $1.13K in Q2 2026.
  • 285 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.